What does Metagenomi Therapeutics, Inc. do?
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a…
What is Metagenomi Therapeutics, Inc.'s P/E and P/B ratio?
Metagenomi Therapeutics, Inc. has a P/E ratio of -0.3 and a P/B ratio of 0.27.
What is Metagenomi Therapeutics, Inc.'s debt-to-equity ratio?
Metagenomi Therapeutics, Inc. has a debt-to-equity ratio of 0.34.
How much does Metagenomi Therapeutics, Inc. owe compared with what it owns?
Metagenomi Therapeutics, Inc. owes $0.35 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Metagenomi Therapeutics, Inc.'s Positivity rank?
Metagenomi Therapeutics, Inc. is ranked #1,335 of 6,774 companies globally and #282 of 4,000 in United States on PositoAI, with a Positivity Score of 22,928.
Does Metagenomi Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Metagenomi Therapeutics, Inc..
Where can I read the latest news about Metagenomi Therapeutics, Inc.?
Recent headlines about Metagenomi Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Metagenomi Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Metagenomi Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.